Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study

MLA

Bridget E Barber, et al. “Safety, Pharmacokinetics, and Antimalarial Activity of the Novel Triaminopyrimidine ZY-19489: A First-in-Human, Randomised, Placebo-Controlled, Double-Blind, Single Ascending Dose Study, Pilot Food-Effect Study, and Volunteer Infection Study.” The Lancet Infectious Diseases, vol. 22, June 2022, pp. 879–90. EBSCOhost, https://doi.org/10.1016/s1473-3099(21)00679-4.

APA

Bridget E Barber, Melissa Fernandez, Hardik Babubhai Patel, Catalina Barcelo, Stephen D Woolley, Harilal Patel, Stacey Llewellyn, Azrin N Abd-Rahman, Sunil Sharma, Mukul Jain, Ashok Ghoghari, Ilaria Di Resta, Aline Fuchs, Ioanna Deni, Tomas Yeo, Sachel Mok, David A Fidock, Stephan Chalon, Jörg J Möhrle, … Kevinkumar Kansagra. (2022). Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study. The Lancet Infectious Diseases, 22, 879–890. https://doi.org/10.1016/s1473-3099(21)00679-4

Chicago

Bridget E Barber, Melissa Fernandez, Hardik Babubhai Patel, Catalina Barcelo, Stephen D Woolley, Harilal Patel, Stacey Llewellyn, et al. 2022. “Safety, Pharmacokinetics, and Antimalarial Activity of the Novel Triaminopyrimidine ZY-19489: A First-in-Human, Randomised, Placebo-Controlled, Double-Blind, Single Ascending Dose Study, Pilot Food-Effect Study, and Volunteer Infection Study.” The Lancet Infectious Diseases 22 (June): 879–90. doi:10.1016/s1473-3099(21)00679-4.